NSE: NATCOPHARM | BSE: 524816

Strong Performer, Under Radar

Download real time

854.60 -0.90 (-0.11%)

43.22% Fall from 52W High

100.4K NSE+BSE Volume

NSE 24 Sep, 2025 10:54 AM (IST)

15,306.7

Market Cap

High in industry

Beta 1Year

Average volatility

Natco Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for NATCOPHARM, BSE:524816 Natco Pharma Ltd.

Natco Pharma Ltd.

14 Dec 2020

854.60

-0.11%

Natco Pharma Limited

Hold: Natco Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Cipla: Owing to competition, we expect Cipla to garner 1-7% market share for volume-limited period and 15% thereafter. Hence, with above market share and a 70-90% price erosion assumption, our gRevlimid NPV arrives at | 41. We maintain BUY rating and arrive at a target price of | 965, including...

Number of MF schemes decreased from 54 to 47 in Jun 2025 qtr

Natco Pharma Ltd.

18 Nov 2020

854.60

-0.11%

NATCO PHARMA

Sell: Natco Pharma Ltd.

Recommendation Target

Geojit BNP Paribas

Q2FY21 on the back of growth in exports of formulations, APIs as well as one-offs like the Revlimid settlement income. India business continued its de-growth during the quarter with a YoY decline of 11% on account of lower oncology and Hep-C sales. The company has stated that it would look to launch the highly anticipated Revlimid in the U.S during FY22. Natco expects the launch of its agrochemical molecules by the end of the year, pending regulatory approval....

Geojit BNP Paribas decreased Hold price target of Natco Pharma Ltd. to 940.0 on 17 Sep, 2025.

Natco Pharma Ltd.

14 Aug 2020

854.60

-0.11%

NATCO PHARMA

Hold: Natco Pharma Ltd.

Recommendation Target

Geojit BNP Paribas

NATCO Pharma (NATCO) is a R&D; focussed, vertically integrated pharmaceutical company with an experienced management team and presence across multiple speciality therapeutic segments. We upgrade our rating from Sell to Hold by valuing Natco at 26x FY22 EPS with a target of Rs.881. We expect the combination of existing products such as Chloroquine, Oseltamivir as well as the launch of Revlimid in the U.S and its focus on other regulated markets to drive overall profitability. Total revenues were up 13% YoY during the quarter led by strong performance in the export formulation and API segments. Formulation exports grew by 29% YoY, led by strong showing in...

Number of MF schemes decreased from 54 to 47 in Jun 2025 qtr

Natco Pharma Ltd.

13 Aug 2020

854.60

-0.11%

Natco Pharma Limited

Buy: Natco Pharma Ltd.

Target

ICICI Securities Limited

Natco has carved out its own identity via tie-ups to tap limited but niche products pipeline including 20 Para IVs filings (FY20). As per the revised and more feasible game plan, it plans to market products via tie-ups with established players in the generic space. Till FY19, the company had filed 51 ANDAs, which includes some niche FTF opportunities. Overall, the...

Natco Pharma Ltd. has an average target of 1294.50 from 4 brokers.

Natco Pharma Ltd.

19 Jun 2020

854.60

-0.11%

Natco Pharma Limited

Buy: Natco Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Natco Pharma Ltd. has an average target of 1294.50 from 4 brokers.

Natco Pharma Ltd.

09 Mar 2020

854.60

-0.11%

NATCO PHARMA

Sell: Natco Pharma Ltd.

Target

Geojit BNP Paribas

Net profit was down 34.5% YoY as other expenses included a one-time provision of 15 cr for bad debts The launch of Revlimid will be dependent on the court trial that will take place in Canada during the month of March...

Natco Pharma Ltd. has lost -40.67% in the last 1 Year

Natco Pharma Ltd.

13 Feb 2020

854.60

-0.11%

Natco Pharma Limited

Hold: Natco Pharma Ltd.

Target

ICICI Securities Limited

Natco has carved out its own identity via tie-ups to tap limited but niche products pipeline including 20 Para IVs filings (FY19). As per the revised and more feasible game plan, it plans to market products via tie-ups with established players in the generic space. Till FY19, the company filed 51 ANDAs, which includes some niche FTF opportunities. Overall, the management expects one or two complex product launches in the US. New launches in CND / Oncology to drive domestic revenues Natco is a leading player in the domestic oncology segment with a product...

Natco Pharma Ltd. has lost -40.67% in the last 1 Year

Natco Pharma Ltd.

14 Jan 2020

854.60

-0.11%

Natco Pharma Ltd - Company Update

Not Rated: Natco Pharma Ltd.

Edelweiss

Natco Pharma (NATCO) is ~ INR 2000 Crore revenue Pharmaceutical company with exposure to the US generics (40%, FY19) and India Formulations (37%) segments.

Number of FII/FPI investors decreased from 385 to 317 in Jun 2025 qtr

Natco Pharma Ltd.

28 Aug 2019

854.60

-0.11%

Natco Pharma Ltd. - Result Update - 28 August 2019

Not Rated: Natco Pharma Ltd.

Way2Wealth

Natco pharma's revenue/EBITDA/PAT declined 11%/16%/20% YoY in Q1FY20. The decline was attributed due to the performance of the formulation segment which de-grew 12% YoY. However, API and subsidiaries reported a growth of 7% and 21% YoY. Despite the decline in...

Number of FII/FPI investors decreased from 385 to 317 in Jun 2025 qtr

Natco Pharma Ltd.

19 Aug 2019

854.60

-0.11%

NATCO PHARMA

Sell: Natco Pharma Ltd.

Target

Geojit BNP Paribas

Natco witnessed YoY de-growth of 11% in sales in Q1FY20 due to poor sales in the US and decline in Hep-C revenue in India. EBITDA was down by 16% (YoY) while the margin down by 270bps on account of lower realisation in the US . Launched first time generics - apixaban and rivaroxaban in India (June) which are globally mega blockbuster molecules. Key drivers of revenue in FY20 will be India, Brazil and Canada which together is expected to see encouraging growth in FY20-21E....

Natco Pharma Ltd. has lost -40.67% in the last 1 Year

Is Natco Pharma Ltd. worth buying?

568 Votes:

Buy 83.27%

Sell 7.39%

Hold 9.33%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf